Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Nov 13, 2018
LEXINGTON, Mass., Nov. 13, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a
Oct 20, 2018
- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit 1  in early analyses LEXINGTON, Mass., Oct. 20 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell
Sep 21, 2018
LEXINGTON, Mass., Sept. 21, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Corporation
Sep 17, 2018
- Payment of $5M received for initiation of Phase 1 trial of LAG-3 antibody - Eligible for up to an additional $505 million for milestones plus royalties on sales LEXINGTON, Mass., Sept. 17, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of